Oryzon Genomics S.A. ORYZF · Stock Open Oryzon Genomics S.A. in new tab
Oryzon Genomics S.A. Analysis (ORYZF)
Is Oryzon Genomics S.A. a good investment? Oryzon Genomics S.A. (ORYZF) is currently trading at 3.36 USD.
Earnings Schedule: Oryzon Genomics S.A. is expected to release its next earnings report on Nov. 6, 2026.
Investor FAQ
Does Oryzon Genomics S.A. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Oryzon Genomics S.A.?
Oryzon Genomics S.A. is classified as a Stock. You can compare it against 8 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 6, 2026. The company currently has a trailing EPS of -0.04.
Company Profile
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
Community Discussion